These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 24630271)

  • 1. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.
    Grabowski GA; Golembo M; Shaaltiel Y
    Mol Genet Metab; 2014 May; 112(1):1-8. PubMed ID: 24630271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease.
    Gupta P; Pastores GM
    Pediatric Health Med Ther; 2017; 8():73-81. PubMed ID: 29388611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
    Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
    Zimran A; Wajnrajch M; Hernandez B; Pastores GM
    Orphanet J Rare Dis; 2018 Feb; 13(1):36. PubMed ID: 29471850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
    Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
    Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
    Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Shankar SP; Petakov M; Giraldo P; Rosenbaum H; Amato DJ; Szer J; Chertkoff R; Brill-Almon E; Zimran A
    Am J Hematol; 2016 Jul; 91(7):661-5. PubMed ID: 27102949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
    Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Elstein D; Paz A; Brill-Almon E; Chertkoff R
    Blood Cells Mol Dis; 2015 Jan; 54(1):9-16. PubMed ID: 25453586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States.
    Farahbakhshian S; Inocencio TJ; Poorman G; Wright E; Pathak RR; Bullano M
    J Med Econ; 2022; 25(1):755-761. PubMed ID: 35611840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gaucher disease and its treatment options.
    Bennett LL; Mohan D
    Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Gaucher disease: enzyme replacement therapy.
    Zimran A; Elstein D
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():82-7. PubMed ID: 25345089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
    Abbas R; Park G; Damle B; Chertkoff R; Alon S
    PLoS One; 2015; 10(6):e0128986. PubMed ID: 26053270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
    Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
    Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.
    Zimran A; Durán G; Mehta A; Giraldo P; Rosenbaum H; Giona F; Amato DJ; Petakov M; Muñoz ET; Solorio-Meza SE; Cooper PA; Varughese S; Chertkoff R; Brill-Almon E
    Am J Hematol; 2016 Jul; 91(7):656-60. PubMed ID: 27174694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
    Zimran A; Durán G; Giraldo P; Rosenbaum H; Giona F; Petakov M; Terreros Muñoz E; Solorio-Meza SE; Cooper PA; Varughese S; Alon S; Chertkoff R
    Blood Cells Mol Dis; 2019 Sep; 78():14-21. PubMed ID: 27499018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
    Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.